Gary Owens, MD, president of Gary Owens Associates, outlines the challenges of screening for pulmonary arterial hypertension (PAH).
Because pulmonary arterial hypertension (PAH) is rare, there really isn't any good screening protocol, said Gary Owens, MD, president of Gary Owens Associates. Owens presented his talk, "The Latest Evidence on Emerging Therapies and Innovations in PAH Management," at this year's National Association of Managed Care Physicians Forum, which is taking place April 21 and 22 in Orlando, Florida.
Transcript
What is the current state of PAH screening and assessment in the United States?
First of all, when we talk about PAH, we're really talking about 1 particular subgroup of a larger group called pulmonary hypertension, of which there are 5 categories. But PAH, pulmonary arterial hypertension, is classified by the World Health Organization as type 1. It's a fairly rare condition as best we know. It might be about 15 cases per 1 million, half of which are genetic and the other half of which are idiopathic.
Because it's a rare disorder, it really doesn't have a good screening protocol, nor is there anything recommended for screening in the guidelines. That being said, patients often present with very nonspecific symptoms and have quite a bit of a protracted journey from presentation of symptoms, which again are nonspecific. Shortness of breath can certainly be due to any number of diseases. That may be often followed by things like fatigue, weakness, chest pain—again, very nonspecific—although in people with PAH, that shortness of breath gets very profound, may even occur at rest. And it's at that point when lots of other conditions have been ruled out, that really the diagnostic journey begins. And that can be pretty complicated. It can take 2 to 3 years sometimes before a patient gets diagnosed.
So the bottom line, not a lot of good screening, and even when symptoms present, because they are very nonspecific, it does take a while to get to a diagnosis and even confirming that diagnosis can be a bit difficult.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More